HLA polymorphism among Chinese patients with chronic plaque psoriasis: Subgroup analysis

British Journal of Dermatology

Volumn 166, Issue 2, 2012, Pages 288-297

  Chiu, H Y ^a   Huang, P Y ^a   Jee, S H ^a   Hu, C Y ^a,b   Chou, C T ^c   Chang, Y T ^c,d   Hwang, C Y ^c   Tsai, T F ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; EFALIZUMAB; ETANERCEPT; HLA B ANTIGEN; HLA B46 ANTIGEN; HLA B60 ANTIGEN; HLA B75 ANTIGEN; HLA C ANTIGEN; HLA CW06 ANTIGEN; HLA CW10 ANTIGEN; UNCLASSIFIED DRUG; USTEKINUMAB;

ADULT; ARTICLE; CASE CONTROL STUDY; CHINESE; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GENETIC DIFFERENCE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS VULGARIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; CHINA; CHRONIC DISEASE; DERMATOLOGIC AGENTS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMANS; MALE; POLYMORPHISM, GENETIC; PSORIASIS; RECOMBINANT FUSION PROTEINS; RISK FACTORS; YOUNG ADULT;

EID: 84862778696     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10688.x     Document Type: Article

References (43)

1. Shao C, Ye G, Hu C, et al. Psoriatic research in China. Int J Dermatol 1992; 31: 840-4.
2. Tiilikainen A, Lassus A, Karvonen J, et al. Psoriasis and HLA-Cw6. Br J Dermatol 1980; 102: 179-84.
3. Gottlieb AB, Krueger JG,. HLA region genes and immune activation in the pathogenesis of psoriasis. Arch Dermatol 1990; 126: 1083-6.
4. Gudjonsson JE, Karason A, Antonsdottir AA, et al. HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features. J Invest Dermatol 2002; 118: 362-5.
5. Gudjonsson JE, Karason A, Runarsdottir EH, et al. Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients-an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 2006; 126: 740-5.
6. Fan X, Yang S, Sun LD, et al. Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population. Acta Derm Venereol (Stockh) 2007; 87: 335-40.
7. Szczerkowska-Dobosz A, Rebala K, Szczerkowska Z, et al. Correlation of HLA-Cw*06 allele frequency with some clinical features of psoriasis vulgaris in the population of northern Poland. J Appl Genet 2004; 45: 473-6.
8. Tsai TF, Hu CY, Tsai WL, et al. HLA-Cw6 specificity and polymorphic residues are associated with susceptibility among Chinese psoriatics in Taiwan. Arch Dermatol Res 2002; 294: 214-20.
9. Chang YT, Tsai SF, Lee DD, et al. A study of candidate genes for psoriasis near HLA-C in Chinese patients with psoriasis. Br J Dermatol 2003; 148: 418-23.
10. Zhang XJ, Zhang AP, Yang S, et al. Association of HLA class I alleles with psoriasis vulgaris in southeastern Chinese Hans. J Dermatol Sci 2003; 33: 1-6.
11. Feng BJ, Sun LD, Soltani-Arabshahi R, et al. Multiple loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet 2009; 5: e1000606.
12. Stuart PE, Nair RP, Hiremagalore R, et al. Comparison of MHC class I risk haplotypes in Thai and Caucasian psoriatics shows locus heterogeneity at PSORS1. Tissue Antigens 2010; 76: 387-97.
13. Costanzo A, Talamonti M, Botti E, et al. HLA-Cw6 allele confers sensitivity to efalizumab treatment in psoriasis. Br J Dermatol 2008; 159: 1392 (Abstract).
14. Stingl G, Monnet E, Costanzo A,. Identification of genetic risk markers of efalizumab response. Br J Dermatol 2008; 159: 1399 (Abstract).
15. Gulliver W, Tomi Z, Pirzada S,. HLA-Cw6 and TNF-α polymorphisms may help predict response to biologic therapy in patients with chronic plaque psoriasis. J Invest Dermatol 2007; 127: S22 (Abstract).
16. Tsai TF, Yeh TY,. The use of biologics for psoriasis in Asia-Pacific region. Curr Rheumatol Rev 2009; 5: 149-52.
17. Tsai TF, Liu MT, Liao YH, et al. Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study. J Eur Acad Dermatol Venereol 2008; 22: 345-52.
18. Huang PH, Liao YH, Wei CC, et al. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study. J Eur Acad Dermatol Venereol 2008; 22: 923-30.
19. Tsai TF, Youn J, Foley P, et al. PRESTA: Asia/Pacific subanalysis. Oral presentation at: Asian Academy of Dermatology and Venereology, 6-7 November 2009, Hanoi, Vietnam.
20. Ardlie KG, Kruglyak L, Seielstad M,. Patterns of linkage disequilibrium in the human genome. Nat Rev Genet 2002; 3: 299-309.
21. Dupont WD, Plummer WD Jr,. Power and sample size calculations. A review and computer program. Control Clin Trials 1990; 11: 116-28.
22. Nakagawa H, Asahina A, Akazaki S, et al. Association of Cw11 in Japanese patients with psoriasis vulgaris. Tissue Antigens 1990; 36: 241-2.
23. Choonhakarn C, Romphruk A, Puapairoj C, et al. Haplotype associations of the major histocompatibility complex with psoriasis in Northeastern Thais. Int J Dermatol 2002; 41: 330-4.
24. Enerbäck C, Martinsson T, Inerot A, et al. Evidence that HLA-Cw6 determines early onset of psoriasis, obtained using sequence-specific primers (PCR-SSP). Acta Derm Venereol (Stockh) 1997; 77: 273-6.
25. Enerbäck C, Martinsson T, Inerot A, et al. Significantly earlier age at onset for the HLA-Cw6-positive than for the Cw6-negative psoriatic sibling. J Invest Dermatol 1997; 109: 695-6.
26. Romphruk AV, Romphruk A, Choonhakarn C, et al. Major histocompatibility complex class I chain-related gene A in Thai psoriasis patients: MICA association as a part of human leukocyte antigen-B-Cw haplotypes. Tissue Antigens 2004; 63: 547-54.
27. Gudjonsson JE, Karason A, Antonsdottir A, et al. Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol 2003; 148: 233-5.
28. Rutter KJ, Watson RE, Cotterell LF, et al. Severely photosensitive psoriasis: a phenotypically defined patient subset. J Invest Dermatol 2009; 129: 2861-7.
29. Cassia FF, Carneiro SC, Marques MT, et al. Psoriasis vulgaris and human leukocyte antigens. J Eur Acad Dermatol Venereol 2007; 21: 303-10.
30. Oka A, Tamiya G, Tomizawa M, et al. Association analysis using refined microsatellite markers localizes a susceptibility locus for psoriasis vulgaris within a 111 kb segment telomeric to the HLA-C gene. Hum Mol Genet 1999; 8: 2165-70.
31. Kim TG, Lee HJ, Youn JI, et al. The association of psoriasis with human leukocyte antigens in Korean population and the influence of age of onset and sex. J Invest Dermatol 2000; 114: 309-13.
32. Kastelan M, Gruber F, Cecuk E, et al. Analysis of HLA antigens in Croatian patients with psoriasis. Acta Derm Venereol (Stockh) 2000; 211 (Suppl.): 12-13.
33. Chang YT, Liu HN, Shiao YM, et al. A study of PSORS1C1 gene polymorphisms in Chinese patients with psoriasis. Br J Dermatol 2005; 153: 90-6.
34. MagalhÃes RF, Biral AC, Pancoto JA, et al. Human leukocyte antigen (HLA) and single nucleotide polymorphisms (SNPs) tumor necrosis factor (TNF)-alpha -238 and -308 as genetic markers of susceptibility to psoriasis and severity of the disease in a long-term follow-up Brazilian study. Int J Dermatol 2010; 49: 1133-40.
35. Kiffmeyer WR, Langer E, Davies SM, et al. Genetic polymorphisms in the Hmong population: implications for cancer etiology and survival. Cancer 2004; 100: 411-17.
36. Wu GQ, Zhao YM, Lai XY, et al. Distribution of killer-cell immunoglobulin-like receptor genes in Eastern mainland Chinese Han and Taiwanese Han populations. Tissue Antigens 2009; 74: 499-507.
37. Lin M, Chu CC, Chang SL, et al. The origin of Minnan and Hakka, the so-called 'Taiwanese', inferred by HLA study. Tissue Antigens 2001; 57: 192-9.
38. Ho PY, Barton A, Worthington J, et al. HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis. Ann Rheum Dis 2007; 66: 807-11.
39. Henseler T, Christophers E,. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450-6.
40. Antoniou C, Dessinioti C, Stratigos A, et al. Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution's experience. J Eur Acad Dermatol Venereol 2009; 23: 979-82.
41. Driessen RJ, Boezeman JB, van de Kerkhof PC, et al. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009; 160: 670-5.
42. de Groot M, Appelman M, Spuls PI, et al. Initial experience with routine administration of etanercept in psoriasis. Br J Dermatol 2006; 155: 808-14.
43. Eder L, Chandran V, Schentag CT, et al. Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. Rheumatology (Oxford) 2010; 49: 1361-6.